# Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

> **NCT00268255** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Barbara Ann Karmanos Cancer Institute**

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** gefitinib
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** enzyme inhibitor therapy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** protein tyrosine kinase inhibitor therapy
- **PROCEDURE:** radiation therapy
- **PROCEDURE:** radiosensitization

## Key facts

- **NCT ID:** NCT00268255
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never moved forward with accrual.
- **Last updated:** 2013-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268255, "Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00268255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*